SynthesisAnnals of hematology2026
Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.
Synthesis in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Both anti-CD19 chimeric antigen receptor (CAR)-T cell therapy and CD20xCD3 bispecific antibodies (BsAbs) are recommended as preferred regimens of third-line and subsequent treatment for follicular lymphoma (FL). We aimed to compare the efficacy and safety of CAR-T and BsAbs in third- or later-line treatments for relapsed or refractory (R/R) FL. We reviewed trials from PubMed, Embase and Cochrane Library databases up to January 31, 2025. Primary endpoint was overall response rate (ORR). Secondary endpoints included complete response rate (CRR), 12-month progression-free survival (PFS), and grade ≥ 3 adverse events of cytokine release syndrome (CRS), neurotoxicity, and infection. Eight studies comprising 725 grade 1-3a FL patients with R/R disease after ≥ 2 lines of systemic therapy were included in the meta-analysis. The pooled ORR was 0.93 (95% CI, 0.84–0.97) for CAR-T and 0.81 (95% CI, 0.77–0.85) for BsAbs (P = 0.02). For safety profiles, no significant difference was observed between the two groups in terms of grade ≥ 3 CRS, neurotoxicity, and infections. Anti-CD19 CAR-T cell therapy exhibited higher ORR compared to CD20xCD3 BsAbs as third- or later-line treatment for R/R FL with comparable toxicities.Registration: PROSPERO 2025 CRD420251005804.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.